SCHEMBL12107976

SCHEMBL12107976

COc1nc2c(cc1Cc1cccc(Cl)c1F)c(=O)c(C(=O)O)cn2C[C@H](O)c1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ METTL3 Q86U44 1/20 0.52
▸ RXFP1 Q9HBX9 2/20 0.39
▸ TP53 P04637 1/20 0.39
▸ POLB P06746 1/20 0.39
▸ TSHR P16473 2/20 0.38
▸ HIF1A Q16665 1/20 0.38
▸ CHRM1 P11229 1/20 0.37
▸ THRB P10828 1/20 0.36
▸ PLA2G4A P47712 2/20 0.36
▸ LMNA P02545 3/20 0.35
▸ ALDH1A1 P00352 2/20 0.35
▸ CYP2C9 P11712 1/20 0.35
▸ ATP6V1B2 P21281 1/20 0.35
▸ TBXA2R P21731 1/20 0.35
▸ EDNRA P25101 1/20 0.35
▸ TARBP2 Q15633 1/20 0.35
▸ MAPT P10636 3/20 0.35
▸ KDM4E B2RXH2 1/20 0.35
▸ HPGD P15428 1/20 0.35
▸ RAB9A P51151 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12107978 1.00 METTL3 (0.52) METTL3RXFP1TP53POLBTSHR
SCHEMBL3656847 0.86 METTL3 (0.48) METTL3RXFP1TP53POLBTHRB
SCHEMBL12107968 0.82 METTL3 (0.61) METTL3RXFP1TP53POLBTSHR
SCHEMBL12107935 0.81 METTL3 (0.64) METTL3RXFP1TP53POLBTSHR
SCHEMBL12107962 0.81 METTL3 (0.59) METTL3RXFP1TP53POLBTSHR
SCHEMBL12107926 0.80 METTL3 (0.72) METTL3RXFP1TP53POLBTSHR
SCHEMBL1300623 0.80 METTL3 (0.72) METTL3RXFP1TP53POLBTSHR
SCHEMBL1300242 0.80 METTL3 (0.72) METTL3RXFP1TP53POLBTSHR
SCHEMBL12107943 0.80 METTL3 (0.58) METTL3RXFP1TP53POLBTSHR
SCHEMBL1301600 0.79 METTL3 (0.60) METTL3RXFP1TP53POLBTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110269741-A1 NOVEL COMPOSITIONS AND METHODS OF USE ARDEA BIOSCIENCES, INC. (US) 2011-11-03 — — US disclosed
US-20110269741-A1 NOVEL COMPOSITIONS AND METHODS OF USE ARDEA BIOSCIENCES, INC. (US) 2011-11-03 — — US disclosed
US-20110166123-A1 NOVEL COMPOSITIONS AND METHODS OF USE AARDEA BIOSCIENCES, INC. (US) 2011-07-07 — — US disclosed
US-20110166123-A1 NOVEL COMPOSITIONS AND METHODS OF USE AARDEA BIOSCIENCES, INC. (US) 2011-07-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110166123-A1 NOVEL COMPOSITIONS AND METHODS OF USE TYMP, SAMHD1, PNP METTL3 2709/4885RXFP1 4815/4885TP53 3051/4885
US-20110269741-A1 NOVEL COMPOSITIONS AND METHODS OF USE TYMP, SAMHD1, PNP METTL3 2709/4885RXFP1 4815/4885TP53 3051/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback